Pasireotide Injection

1. Anti secretion effect
The anti secretion effect of pasiretide is its most fundamental and core pharmacological effect. Somatostatin receptor (SSTR) belongs to the G protein coupled receptor (GPCR) superfamily. When pasireotide binds to SSTR on the membrane surface of pituitary gland cells, pancreatic beta cells, intestinal endocrine cells, and neuroendocrine tumor cells, it can activate the Gi/GO type G protein coupled to it, thereby inhibiting the activity of adenylyl cyclase (AC), leading to a significant decrease in intracellular adenosine monophosphate (cAMP) levels. As a key second messenger, the decrease in concentration of cAMP can further inhibit the activation of protein kinase A (PKA), reduce the transcription of hormone synthesis related genes and the release of hormone granules, thereby achieving strong inhibition of multiple hormone secretion.

Specifically, Paxiretide can effectively inhibit the secretion of the following hormones:
Growth hormone (GH): In pituitary growth hormone adenoma cells, pasiretide inhibits the synthesis and release of GH by reducing cAMP levels, while also inhibiting growth hormone releasing hormone (GHRH) - induced GH secretion. This effect has been fully validated in vitro experiments. In primary culture of rat pituitary cells, pasiretide can effectively inhibit GHRH induced GH release, with a half maximal inhibitory concentration (IC ₅₀) of only 0.4 nM, which is much better than octreotide (IC ₅₀ is about 3-5 nM), fully demonstrating the excellent efficacy of pasiretide in GH inhibition .
Insulin like growth factor-1 (IGF-I): After the secretion of GH is inhibited, the stimulation signal for liver synthesis of IGF-I weakens, and the serum IGF-I level decreases accordingly. In patients with acromegaly, the decrease in IGF-I levels after treatment with paclitaxel can typically reach 40% -60%.

Corticotropin stimulating hormone (ACTH): In pituitary ACTH adenoma cells of patients with Cushing's disease, pasiretide strongly inhibits ACTH secretion through the SSTR5 mediated signaling pathway. Due to the high overexpression of SSTR5 and low expression of SSTR2 in human ACTH adenomas, the ultra-high affinity of pasiretide for SSTR5 significantly outperforms traditional SSTR2 selective agonists (such as octreotide) in ACTH inhibition.
Other hormones: Pachiride can also inhibit the secretion of various gastrointestinal and pancreatic endocrine hormones such as insulin, glucagon, gastrin, vasoactive intestinal peptide (VIP), serotonin, etc. It is precisely because of its inhibitory effect on insulin secretion that high blood sugar has become the most common and concerning adverse reaction of paclitaxel (see Section 6 for safety discussion).

It is worth emphasizing that the anti secretion spectrum breadth of pasiretide far exceeds that of traditional somatostatin analogs. Octreotide and lanreotide mainly target SSTR2, with low affinity for SSTR1, 3, and 5; And Pasiretide has high affinity at the nanomolar level for SSTR1/2/3/5 (pKi values of 8.2/9.0/9.1/9.9, respectively), which means that it can exert anti secretory effects through multiple receptor signaling pathways simultaneously, thus outperforming first generation drugs in terms of depth and breadth of hormone inhibition.

2. Anti proliferative and pro apoptotic effects
The pharmacological value of pasireotide injection is not limited to hormone inhibition. More and more research evidence shows that the drug also has significant antiproliferative and pro apoptotic activities, which gives it unique advantages in the field of tumor therapy.
(1) Anti proliferative mechanism

The anti proliferative effect of pasiretide is mainly achieved through the following molecular pathways:

Inhibition of cAMP/PKA pathway: After SSTR activation, Gi protein mediated adenylate cyclase inhibition not only reduces cAMP levels to inhibit hormone secretion, but also affects the expression of cell cycle regulatory proteins (such as Cyclin D1 and Cyclin E) by inhibiting PKA activity, thereby blocking cells in the G0/G1 phase and inhibiting cell proliferation.

MAPK/ERK pathway regulation: Pachiride can activate protein tyrosine phosphatases (such as SHP-1) through SSTR2 and SSTR5, dephosphorylate and inhibit the Ras/Raf/MEK/ERK signaling cascade, which is one of the key driving factors for cell proliferation.

Inhibition of the PI3K/Akt/mTOR pathway: Studies have shown that pasiride can downregulate the activity of the PI3K/Akt signaling pathway, thereby inhibiting the function of mTOR complex 1 (mTORC1), reducing protein synthesis and cell growth.

(2) Mechanisms of promoting apoptosis
The mechanism of inducing apoptosis of tumor cells by pasiretide involves the synergistic effect of multiple signaling pathways:
Mitochondrial pathway (endogenous pathway): Pachiride can upregulate the expression of pro apoptotic protein Bax and downregulate the expression of anti apoptotic protein Bcl-2, leading to a decrease in mitochondrial membrane potential, release of cytochrome C into the cytoplasm, activation of Caspase-9/Caspase-3 cascade reaction, and ultimately inducing cell apoptosis.

Death receptor pathway (exogenous pathway): Some studies suggest that pasiretide can upregulate the expression of Fas/FasL and TRAIL receptors on the surface of tumor cells, activating the exogenous apoptotic pathway.

(3) Independence of anti secretion and anti proliferation
An extremely important discovery is that the anti ACTH secretion and anti cell proliferation effects of paclitaxel in human pituitary ACTH adenomas are two independent mechanisms. This means that even in cases where hormone secretion is effectively inhibited, pasiretide can still independently play a role in reducing tumor volume, which has significant clinical implications for diseases such as Cushing's disease that require long-term treatment - patients can not only achieve biochemical relief, but may also achieve substantial tumor reduction.

3. Anti inflammatory and analgesic effects
In recent years, the potential therapeutic value of paclitaxel in inflammatory diseases has attracted widespread attention from researchers. SSTR is not only expressed in endocrine cells, but also abundantly expressed in immune cells such as macrophages, T lymphocytes, and neutrophils, providing a molecular basis for the anti-inflammatory effects of somatostatin analogs.
This study used a mouse immune-mediated arthritis model (K/BxN serum metastatic arthritis model) to systematically compare the anti-inflammatory and analgesic effects of pasireotide and octreotide, and made the following key findings:

The study published by Imhof et al. (2011) in Arthritis&Rheumatism is a milestone work in this field. This study revealed an important mechanistic difference: although both pasiretide and octreotide can exert anti-inflammatory and analgesic effects through SSTR2, pasiretide can activate a wider range of downstream signaling pathways (such as inhibiting NF - κ B activation and reducing the release of pro-inflammatory cytokines TNF - α, IL-1 β, and IL-6) by simultaneously binding to SSTR1/3/5, making it superior to octreotide in terms of anti-inflammatory and analgesic effects.
This discovery suggests that pasireotide injection may have potential therapeutic value in autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, and is worthy of further clinical exploration.